2017•Gynecologic OncologyRequires access

Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel

Peter G. Rose, James Java, David M. O’Malley, Melissa A. Geller, Franco M. Muggia, D. K. Armstrong, Michael A. Bookman, Mark F. Brady, Larry J. Copeland

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Gynecologic oncology, Medicine, Oncology, Paclitaxel, Nomogram, Internal medicine, Ovarian cancer, Randomized controlled trial

Back to paper search Browse research topics Original source

Nomogram predicting individual survival following recurrence in advanced stage high-grade ovarian cancer from NRG Oncology/Gynecologic Oncology Group randomized trials of platinum and paclitaxel — Research Paper | ScholarLens